Baselaunch alumnus T3 Pharma acquired by Boehringer Ingelheim
T3 Pharma, which uses live bacteria to deliver immune-modulating proteins to cancer cells, has been acquired for up to 450M Swiss francs.
More details on the BaseLaunch website.
T3 Pharma, which uses live bacteria to deliver immune-modulating proteins to cancer cells, has been acquired for up to 450M Swiss francs.
More details on the BaseLaunch website.